Associated Papers
Benchmarking AlphaMissense Pathogenicity Predictions Against Cystic Fibrosis Variants.
McDonald EF et al.
Biorxiv : the Preprint Server for Biology, 2024
37873426 (PubMed )
Supplement: media-4.xlsx › Sheet1
Benchmarking AlphaMissense pathogenicity predictions against cystic fibrosis variants.
McDonald EF et al.
Plos One, 2024
38271453 (PubMed )
Supplement: pone.0297560.s010.xlsx › Supp_Table_3
A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients.
Jiang JX et al.
Stem Cell Reports, 2021
34678210 (PubMed )
Supplement: mmc3.pdf
Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A>G.
Silva IAL et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2020
Select a paper to view details